Caricamento...
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, includi...
Salvato in:
| Pubblicato in: | Leukemia |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6087717/ https://ncbi.nlm.nih.gov/pubmed/30030507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0210-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|